DiaMedica Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

DiaMedica Therapeutics

10/03/2023 11:45

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports 
results on March 13 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for DiaMedica
Therapeutics
Inc is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $8​, above​ its last closing price of $1.73.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.13       -0.15      -0.12     Beat    18.6
 Jun. 30 2022  -0.17       -0.18      -0.13     Beat    27.8
 Mar. 31 2022  -0.16       -0.21      -0.13     Beat    39.1​
 Dec. 31 2021              -0.18      -0.10     Beat    43.2
 ​​Sep.        -0.21       -0.23      -0.18     Beat    21.1
 30 2021                                                
 Jun. 30 2021  -0.20       -0.21      -0.17     Beat    19.7​
 Mar. 31 2021  -0.21       -0.21      -0.19     Beat    10.9
 Dec. 31 2020  -0.18       -0.17      -0.23     Missed  -36.9
 This summary was machine generated March 10 at 11:45 GMT.  All
figures in US dollars  unless otherwise stated